Participation may include memory testing, bloodwork, MRI and PET brain imaging, and other assessments to monitor treatment effects and safety. Study Phase: Phase 2 Investigational Treatment: SAR448851 Sponsor: Sanofi Eisai DUNK Toronto Memory Program is participating in DUNK, an early-phase clinical research study sponsored by Eisai. The study is investigating an experimental oral medication called E2511 in individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Researchers are evaluating the safety of E2511 and how it affects biological processes involved in memory and brain function. The study also includes a comparison with donepezil, a medication already used to treat symptoms of Alzheimer’s disease.
Who May Qualify?
If you are interested in participating, please complete the following preliminary qualification form.
We will follow-up with you after we have received your submission.